Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6397Neoplasms 5369Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2709Colorectal Neoplasms 2679Lung Neoplasms 2269Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1554Leukemia, Myeloid, Acute 1540Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1424Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1283Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1160Carcinoma, Hepatocellular 1142Stomach Neoplasms 1130Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1053Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 978Uterine Cervical Neoplasms 927Glioblastoma 921Carcinoma, Renal Cell 883Lymphoma, Large B-Cell, Diffuse 854Hodgkin Disease 777

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HER-2 Gene Amplification × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡